Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

Inclusion Criteria:

Males aged ≥ 18 years old
Males with histologically confirmed carcinoma of the prostate
Subjects who are judged by the attending physician and/or Principal Investigator to be a candidate for androgen ablation therapy
Baseline morning serum testosterone level > 150 ng/dL performed at Screening Visit
Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 2
Life expectancy of at least 18 months

Laboratory values

Absolute neutrophil count ≥ 1,500 cells/µL
Platelets ≥ 100,000 cells/µL
Hemoglobin ≥ 10 gm/dL
Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
AST (SGOT) ≤ 2.5 × ULN
ALT (SGPT) ≤ 2.5 × ULN
Serum creatinine ≤ 1.5 mg/dL
Lipid profile within acceptable range according to investigator's opinion
Serum glucose within acceptable range according to investigator's opinion
HgbA1c within acceptable range according to investigator's opinion
Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment
Serum glucose within acceptable range according to investigator's judgement
Urinalysis within normal range according to the investigator's judgment
Agree to use male contraceptive methods during study trial
Based on the Investigator's judgment, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol
All aspects of the protocol explained and written informed consent obtained

Exclusion Criteria:

Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of carcinoma of the prostate. Radiation for pain control will be allowed during the study.
Receipt of any vaccination (including influenza) within 4 weeks of screening visit
History of blood donation within 2 months of screening visit
History of anaphylaxis to any LH-RH analogues
Receipt of any LHRH suppressive therapy within 6 months of screening visit
Major surgery, including any prostatic surgery, within 4 weeks of screening visit
History and concomitant clinical and radiographic evidence of central nervous system/spinal cord metastases and subjects at risk for spinal cord compression
Clinical evidence of active urinary tract obstruction and subjects at risk for urinary obstruction
History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
History or presence of hypogonadism, or receipt of exogenous testosterone supplementation within 6 months of Baseline
Clinically significant abnormal ECG and/or history of clinically significant cardiovascular disease as judged by the investigator
History of drug and/or alcohol abuse within 6 months of Baseline
Contraindication to leuprolide or an LHRH agonist as indicated on package labeling
Use of 5-alpha reductase inhibitor within the last 6 months of screening visit
History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well controlled diabetes mellitus Type II will be allowed if only oral hypoglycemic are required. Prostate cancer subjects with poor controlled diabetes mellitus with Hb1Ac > 9.5% or urine glycosuria > 1.0 g/dL should be excluded.
Use of systemic corticosteroids at a dose >10 mg/d or anti-androgens
Use of any investigational agent within 4 weeks of screening visit
Use of any over-the-counter (OTC) medication within 4 weeks of screening visit except for those listed in the permitted Concomitant Treatment section.
Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor